Daniel Vorobiof

Medical Oncology, Sandton Oncology Center, South Africa

Born in Argentina, where he studied at the University of Cordoba and completed his medical degree at the end of 1972. Dr Vorobiof is a registered Specialist Physician with the sub-speciality of Medical Oncology. At present and for the past 14 years, he is in private practice as a Medical Oncologist and the Oncology Director of the Sandton Oncology Centre, Johannesburg.

He has a MD degree from the University of Pretoria and has published more than 100 articles and abstracts. He is a member of several national and international oncologic societies, as well as an elected member to the International Committee of the American Society of Clinical Oncology (ASCO) and a member of the Developing Countries Task Force (DCTF) of the European Society of Medical Oncology (ESMO).

Dr Vorobiof was the editor of “Understanding Oncology”, for 8 years from its inception. He is on the editorial board of various oncologic related medical journals. He is the current Editor of the Annals of Oncology, Southern Africa Excerpts Edition.

Founder member and past Chairman (1999-2005) of the South African Society of Medical Oncology (SASMO). Founder and past Chairman of the South African Melanoma Advisory Board. Founder member of the International Oncology Foundation (IOF).

Research Interests: For the past 12 years he has been involved in clinical research nationally and internationally with the International Breast Cancer Study Group, the WHO Melanoma Group, the EORTC, SAKK and with other multicentric co-operative clinical trials in South Africa, Europe and North America.

“If or when cancer is going to be conquered, it will be through the hard work of multidisciplinary teams including a variety of scientists and physicians committed to doing what is right for, and in the best interests of people with cancer.”

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Oncology > Oncology Agents (since 15 November 2005)

All recent recommendations

• 6.0
  HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
  Recommended by Daniel Vorobiof
  
• 6.0
  Emerging therapeutic options for breast cancer chemotherapy during pregnancy.
  Recommended by Daniel Vorobiof
  
• 3.0
  Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.
  Recommended by Daniel Vorobiof
  
• 3.0
  Artificial sweeteners and cancer risk in a network of case-control studies.
  Recommended by Daniel Vorobiof
  
• 3.0
  Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
  Recommended by Daniel Vorobiof
  
• 6.6
  Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
  Recommended by Debu Tripathy, Daniel Vorobiof, Nicola Normanno
  
• 6.0
  The use of bisphosphonates in elderly cancer patients.
  Recommended by Daniel Vorobiof
  
• 6.0
  An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial.
  Recommended by Daniel Vorobiof
  
• 3.0
  Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.
  Recommended by Daniel Vorobiof